[go: up one dir, main page]

MX2022005503A - Composiciones farmaceuticas de apixaban de desintegracion oral. - Google Patents

Composiciones farmaceuticas de apixaban de desintegracion oral.

Info

Publication number
MX2022005503A
MX2022005503A MX2022005503A MX2022005503A MX2022005503A MX 2022005503 A MX2022005503 A MX 2022005503A MX 2022005503 A MX2022005503 A MX 2022005503A MX 2022005503 A MX2022005503 A MX 2022005503A MX 2022005503 A MX2022005503 A MX 2022005503A
Authority
MX
Mexico
Prior art keywords
apixaban
pharmaceutical compositions
pharmaceutically acceptable
present
oral disintegration
Prior art date
Application number
MX2022005503A
Other languages
English (en)
Inventor
Balvir Singh
Ramesh Shingala
Shivang Prajapati
Original Assignee
Unison Pharmaceuticals Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unison Pharmaceuticals Pvt Ltd filed Critical Unison Pharmaceuticals Pvt Ltd
Publication of MX2022005503A publication Critical patent/MX2022005503A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a unas formas de dosificación farmacéutica que se desintegran oralmente de apixabán o una sal o profármaco farmacéuticamente aceptable del mismo: la presente invención específicamente se refiere a una composición farmacéutica estable que se desintegra oralmente que comprende apixabán y uno o más excipientes farmacéuticamente aceptables; además, la presente invención se refiere a una forma de dosificación que se desintegra oralmente que comprende apixabán, por lo menos un excipiente de desintegración y opcionalmente uno o más excipientes farmacéuticamente aceptables para el tratamiento de trastornos asociados con el Factor Xa.
MX2022005503A 2019-11-13 2020-10-31 Composiciones farmaceuticas de apixaban de desintegracion oral. MX2022005503A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921046107 2019-11-13
PCT/IN2020/050919 WO2021095048A1 (en) 2019-11-13 2020-10-31 Orally disintegrating pharmaceutical compositions of apixaban

Publications (1)

Publication Number Publication Date
MX2022005503A true MX2022005503A (es) 2022-06-02

Family

ID=75911423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005503A MX2022005503A (es) 2019-11-13 2020-10-31 Composiciones farmaceuticas de apixaban de desintegracion oral.

Country Status (18)

Country Link
US (1) US12508254B2 (es)
EP (2) EP4640220A3 (es)
JP (1) JP2023502209A (es)
KR (1) KR20220101103A (es)
AU (3) AU2020384737A1 (es)
BR (1) BR112022008551A2 (es)
ES (1) ES3037688T3 (es)
HR (1) HRP20250950T1 (es)
HU (1) HUE073416T2 (es)
MA (1) MA55568A (es)
MD (1) MD3946277T2 (es)
MX (1) MX2022005503A (es)
PH (1) PH12022551126A1 (es)
PL (1) PL3946277T3 (es)
RS (1) RS67114B1 (es)
SM (1) SMT202500292T1 (es)
WO (1) WO2021095048A1 (es)
ZA (1) ZA202204907B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551126A1 (en) 2019-11-13 2023-08-23 Unison Pharmaceuticals Pvt Ltd Orally disintegrating pharmaceutical compositions of apixaban
JP2024057549A (ja) * 2022-10-12 2024-04-24 日本ジェネリック株式会社 アピキサバンを含有する錠剤

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533465A (ja) 1998-12-23 2002-10-08 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としての窒素を含む複素二環類
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2011220775B2 (en) 2010-02-25 2015-09-24 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban formulations
CN102058889A (zh) 2010-11-05 2011-05-18 王定豪 包含抗凝血类药物的分散片及其应用
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
US20130064888A1 (en) 2011-08-08 2013-03-14 Roey Solomonovich Pharmaceutical formulations
AU2013323435C1 (en) 2012-09-26 2018-04-12 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban liquid formulations
CN102908324A (zh) 2012-10-31 2013-02-06 南京正科制药有限公司 一种阿哌沙班片
WO2015046219A1 (ja) * 2013-09-27 2015-04-02 株式会社ダイセル 崩壊性粒子組成物を含む口腔内崩壊錠剤
JPWO2015045604A1 (ja) * 2013-09-30 2017-03-09 富士フイルム株式会社 口腔内崩壊錠
CN104644593A (zh) 2013-11-23 2015-05-27 天津市汉康医药生物技术有限公司 阿哌沙班组合物及其制备方法
CA2934120A1 (en) 2013-12-23 2015-07-02 Laboratorios Del Dr. Esteve, S.A. Oral pharmaceutical composition
WO2015103230A1 (en) 2013-12-31 2015-07-09 Ascendia Pharmaceuticals, Llc Pharmaceutical compositions for poorly water-soluble compounds
EP2907507A1 (en) 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
CN103830199A (zh) 2014-03-24 2014-06-04 重庆东得医药科技有限公司 含阿哌沙班的药用制剂及其制备方法
CN104095823A (zh) 2014-07-08 2014-10-15 成都克莱蒙医药科技有限公司 一种阿哌沙班片剂的制备方法
CN104173313B (zh) 2014-08-25 2017-05-17 杭州朱养心药业有限公司 利伐沙班片剂药物组合物
CN104490834A (zh) 2014-12-13 2015-04-08 天津宜耀科技有限公司 一种阿哌沙班片剂的制备方法
CN104523619A (zh) 2014-12-13 2015-04-22 天津宜耀科技有限公司 一种阿哌沙班片剂及其制备方法
CN104490841B (zh) 2014-12-19 2017-06-30 河南润弘制药股份有限公司 一种阿哌沙班片及其制备方法
CN105982870B (zh) 2015-02-03 2020-05-01 山东新时代药业有限公司 一种阿哌沙班片剂
CN106913528A (zh) 2015-12-25 2017-07-04 中美华世通生物医药科技（武汉）有限公司 阿哌沙班微丸及其制备方法
US10537524B2 (en) * 2016-01-12 2020-01-21 North & South Brother Pharmacy Investment Company Limited Apixaban solid composition and preparation method thereof
EP3195860A1 (de) 2016-01-22 2017-07-26 STADA Arzneimittel AG Verfahren zur herstellung eines apixaban-granulates
IN201641006652A (es) * 2016-02-25 2017-11-24
WO2017163170A1 (en) 2016-03-21 2017-09-28 Sun Pharmaceutical Industries Limited Pharmaceutical composition comprising apixaban
WO2017182908A1 (en) 2016-04-18 2017-10-26 Emcure Pharmaceuticals Limited Pharmaceutical compositions of apixaban
CN105832672A (zh) 2016-05-06 2016-08-10 杭州容立医药科技有限公司 一种固体分散体的制备方法和应用
CN105943536A (zh) 2016-05-06 2016-09-21 杭州容立医药科技有限公司 一种固体分散体的制备方法及其应用
EP3243505A1 (en) 2016-05-13 2017-11-15 Zaklady Farmaceutyczne Polpharma SA A pharmaceutical composition comprising amorphous apixaban
CN106822006B (zh) 2016-06-08 2020-08-28 北京普德康利医药科技发展有限公司 一种阿哌沙班片及其制备方法
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
CN107661301A (zh) * 2016-07-29 2018-02-06 天津市汉康医药生物技术有限公司 一种阿哌沙班药物组合物及其制备方法
CN107773549A (zh) 2016-08-24 2018-03-09 天津市汉康医药生物技术有限公司 一种阿哌沙班片及制备方法
CN106420651B (zh) 2016-09-28 2019-03-08 乐普药业股份有限公司 一种阿哌沙班片的制备方法
TWI812602B (zh) * 2016-12-01 2023-08-21 日商第一三共股份有限公司 含二胺衍生物之口腔崩散錠及其製造方法
WO2018150286A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Pharmaceutical composition of apixaban
JP6832753B2 (ja) * 2017-03-09 2021-02-24 旭化成株式会社 セルロース複合体
TR201722523A2 (tr) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Api̇ksaban i̇çeren kati oral farmasöti̇k kompozi̇syonlar
CN107898824A (zh) 2017-12-28 2018-04-13 广东伊茗药业有限公司 一种阿哌沙班片剂
CN108096205A (zh) 2018-02-27 2018-06-01 南京正科医药股份有限公司 一种阿哌沙班片及其制备方法
KR102128321B1 (ko) 2018-03-13 2020-06-30 주식회사 종근당 아픽사반을 포함하는 가용화를 위한 약제학적 제제 및 이의 제조 방법
WO2019204193A1 (en) 2018-04-16 2019-10-24 Bristol-Myers Squibb Company Apixaban formulations
CN108553441B (zh) 2018-06-08 2019-11-08 北京阳光诺和药物研究有限公司 一种阿哌沙班片及其制备方法
WO2020030991A1 (en) 2018-08-09 2020-02-13 Nal Pharmaceutical Group Limited Dosage form for insertion into the mouth
CN108904461A (zh) 2018-09-07 2018-11-30 无锡凯夫制药有限公司 一种阿哌沙班片的制备方法
CN109010273B (zh) 2018-10-08 2021-03-19 中国药科大学 一种阿哌沙班纳米混悬剂及其制备方法
EP3669866A1 (en) 2018-12-19 2020-06-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apixaban
CN109528674A (zh) 2018-12-20 2019-03-29 南京海辰药业股份有限公司 一种含亲水形式的阿哌沙班药物组合物及其制备方法
CN109464415B (zh) 2019-01-09 2021-08-17 常州恒邦药业有限公司 阿哌沙班药物组合物及其制备方法
CN109793715B (zh) 2019-03-15 2022-02-15 南京卡文迪许生物工程技术有限公司 一种阿哌沙班口服固体制剂及其制备方法
CN110123770A (zh) 2019-06-20 2019-08-16 常州恒邦药业有限公司 一种阿哌沙班药物组合物及其制备方法
CN110772490A (zh) 2019-10-31 2020-02-11 宁波高新区美诺华医药创新研究院有限公司 一种阿哌沙班片剂的制备方法
PH12022551126A1 (en) 2019-11-13 2023-08-23 Unison Pharmaceuticals Pvt Ltd Orally disintegrating pharmaceutical compositions of apixaban
CN110934839B (zh) 2019-12-31 2022-02-25 常州恒邦药业有限公司 一种阿哌沙班口服片剂及其制备方法
CN111000820A (zh) 2020-01-09 2020-04-14 新发药业有限公司 一种阿哌沙班片
CN111214442B (zh) 2020-02-13 2021-12-10 山东百诺医药股份有限公司 一种阿哌沙班共微粉化物
CN111494326A (zh) 2020-04-11 2020-08-07 南京正大天晴制药有限公司 一种阿哌沙班片及其制备方法
CN113041227A (zh) 2021-03-03 2021-06-29 河北常山生化药业股份有限公司 一种阿哌沙班片剂及其制备方法

Also Published As

Publication number Publication date
EP3946277B1 (en) 2025-07-09
HRP20250950T1 (hr) 2025-10-24
US12508254B2 (en) 2025-12-30
EP3946277C0 (en) 2025-07-09
PL3946277T3 (pl) 2025-10-06
PH12022551126A1 (en) 2023-08-23
EP3946277A1 (en) 2022-02-09
JP2023502209A (ja) 2023-01-23
AU2025202791A1 (en) 2025-05-08
KR20220101103A (ko) 2022-07-19
WO2021095048A1 (en) 2021-05-20
US20220211689A1 (en) 2022-07-07
RS67114B1 (sr) 2025-09-30
EP3946277A4 (en) 2022-06-15
ES3037688T3 (en) 2025-10-06
MA55568A (fr) 2022-02-09
ZA202204907B (en) 2024-03-27
AU2023203908A1 (en) 2023-07-06
AU2020384737A1 (en) 2022-05-26
SMT202500292T1 (it) 2025-09-12
BR112022008551A2 (pt) 2022-08-09
EP4640220A2 (en) 2025-10-29
CA3156572A1 (en) 2021-05-20
EP4640220A3 (en) 2026-01-28
AU2023203908B2 (en) 2025-01-23
HUE073416T2 (hu) 2026-01-28
MD3946277T2 (ro) 2025-11-30

Similar Documents

Publication Publication Date Title
MX2021013817A (es) Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
MX2018008021A (es) Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
MX2017016276A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol.
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
WO2019203771A3 (en) Solid oral pharmaceutical compositions comprising sitagliptin
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
MX2022005503A (es) Composiciones farmaceuticas de apixaban de desintegracion oral.
BR112023025552A2 (pt) Composições estabilizadas de apilimod e usos das mesmas
MX2020008360A (es) Forma cristalina de bictegravir sodico.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
UY31363A1 (es) Composiciones farmaceuticas que comprenden la combinacion de un agente antiflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas
ECSP15033649A (es) Un medicamento combinado que comprende fenilefrina y paracetamol
CL2018003707A1 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo.
CL2022000095A1 (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
CO2021000158A2 (es) Composición farmacéutica que contiene un péptido
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
NI201300142A (es) Composición farmacéutica para uso en inflamación y dolor.
CO2019013645A2 (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
MX388249B (es) Composición farmacéutica de desloratadina para ser administrada por vía oral, para el tratamiento de enfermedades relacionadas con la histamina.